Bayer, Mammoth Biosciences to team up for novel gene editing tech
Category: #headlines  | By Nikita Chaurasia  | Date: 2022-01-11 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Bayer, Mammoth Biosciences to team up for novel gene editing tech

Pharmaceutical and life sciences company Bayer AG has reportedly entered into a strategic collaboration and option agreement with Mammoth Biosciences Inc., a company that is harnessing nature's diversity to power novel CRISPR products, to use Mammoth’s CRISPR systems for creating in vivo gene-editing therapies.

Developed by Mammoth Biosciences, the revolutionary gene-editing technology is both a crucial enabler and a stand-alone therapeutic approach. It will help Bayer accelerate the development of breakthrough therapies for patients while also bolstering the company's newly developed cell and gene therapy platform. As per the agreement, the two businesses will begin their collaboration by focusing on liver-targeted disorders.

Notably, the development of cell and gene therapies is the next major step in the drug development field. They may be capable of permanently curing diseases with a one-time treatment by addressing the fundamental cause of disorders.

When used outside the living body (ex vivo), gene editing is a crucial enabler for cell treatments, and when used inside the living body, it enables therapeutic targeting of a variety of genetic illnesses with a high unmet medical need (in vivo).

The exclusive toolset of ultra-small Cas enzymes developed by Mammoth Biosciences, including Cas14 and Cas, enables high-fidelity gene editing to be paired with targeted systemic administration. Bayer now has access to this innovative gene-editing technology, which has the potential for increased in vivo applicability owing to the ultra-compact size of these innovative CRISPR systems.

Mammoth Biosciences will be paid around USD 40 million in advance and will be eligible for target option exercise fees and potential future payments in the amount of more than USD 1 billion after certain research & development, as well as commercial landmarks are achieved across 5 preselected in vivo indications, with a primary emphasis on liver-targeted diseases, as per the terms of the agreement.

Bayer will also provide research funds and tiered royalties up to a low double-digit percentage of net sales. On a nonexclusive basis, the companies are also looking to work on ex vivo projects.

Source Credits: https://www.businesswire.com/news/home/20220109005059/en/Bayer-and-Mammoth-Biosciences-to-Collaborate-on-Novel-Gene-Editing-Technology

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...